- Home
- / Nascent Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Nascent Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.1
2024-10-29
Market Capitalization
$13.8 M
2024-10-29
Revenue
$1 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 17, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.0M | 750.0K | 1.0M | |||||||
| Cost of goods sold | 319.5K | |||||||||
| General and administrative expense | 469.8K | 4.3M | 1.6M | 1.0M | 1.1M | 320.9K | 359.3K | 379.4K | 405.3K | 403.6K |
| Operating expense total | 2.1M | 4.3M | 2.1M | 2.2M | 1.4M | 614.6K | 675.8K | 514.6K | ||
| EBIT | (2.1M) | (3.9M) | 1.4M | (2.2M) | (1.4M) | (3.4M) | (1.4M) | (457.1K) | (2.2M) | (2.2M) |
| EBIT margin, % | 47.6% | |||||||||
| Interest income | 61.0 | 4.0 | 141.0 | 125.0 | 41.0 | 5.0 | 12.0 | 274.0 | 5.3K | |
| Interest expense | 1.6M | |||||||||
| Pre tax profit | 1.4M | (2.2M) | (1.4M) | (4.0M) | (958.8K) | (470.4K) | (2.8M) | (2.1M) | ||
| Income tax expense | 240.0K | |||||||||
| Net Income | (2.2M) | (4.1M) | 1.1M | (2.2M) | (1.4M) | (4.0M) | (958.8K) | (470.4K) | 2.8M | (2.1M) |